Leerink Swann analysts saw promise in a pair of "tidbits" about Edwards Lifesciences’ (NYSE:EW) Sapien XT transcatheter aortic valve implantation system presented at the EuroPCR conference in Paris this week.
EuroPCR
EuroPCR: Disappearing stents and bioabsorbable polymers
Disappearing technology had a strong presence at this year’s EuroPCR conference in Paris, with rival device makers demonstrating the safety and efficacy of their next-generation stents.
Elixir Medical unveiled 1st-in-man clinical results for its DESolve fully bioabsorbable drug-eluting scaffold system, a stent made from a proprietary polymer and coated in novolimus. The entire stent is designed to be absorbed by the body in 1-2 years.
EuroPCR: St. Jude’s Enlightn lowers blood pressure faster than rival systems
St. Jude Medical’s (NYSE:STJ) newly cleared Enlightn renal denervation system lowered patients’ blood pressure by twice as much as rival systems in the same amount of time, according to a new study.
Preliminary findings from a study of the Enlightn system found that patients with hypertension saw a 28 point reduction in blood pressure after 30 days.
EuroPCR: Warnings on TAVI in replacing surgically implanted prosthetic valves
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.
EuroPCR: Medtronic touts clearances and findings for its stents and balloons
Medical device titan Medtronic (NYSE:MDT) touted a string of new indications for its Resolute Integrity drug-eluting stents at this year’s EuroPCR meeting in Paris.
With new clearances in hand, the Resolute Integrity stent is now the DES with the broadest range of indications in Europe and the only DES on the market with indication for treating bifurcated lesions, according to a press release.
Boston Scientific’s Lotus TAVI system minimizes leakage in early trial
Boston Scientific’s (NYSE:BSX) Lotus transcatheter aortic valve implantation system fared well in an early feasibility study in patients with severe symptomatic aortic stenosis who were to sick to undergo open-heart surgery.